AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an

Tweet Author

Tweet Content

AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an agreement with generic manufacturers challenging Rinvoq patents. UPA is their 2nd leading product with nearly $3.75 billion worldwide sales in 1st 1/2 of

12 September 2025

Hitting the Target: T2T Therapy in SLE

Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s plenary session lecture on Treat to Target in SLE: Current Evidence and Future Directions, presented during the recent APLAR 2025 Congress.

Antifibrotics - A New Class of Therapies in Rheumatology? Rheumatologists typically manage systemic autoimmune rheumat

Tweet Author

RheumNow

Tweet Content

Antifibrotics - A New Class of Therapies in Rheumatology? Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic https://t.co/IobQagC0ZE

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD

9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, id

Tweet Author

RheumNow

Tweet Content

9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd

Flow cytometry on Peripheral blood can help patient stratification in RA A cluster rich in TEMRA Terminally Differentia

Tweet Author

AurelieRheumo

Tweet Content

Flow cytometry on Peripheral blood can help patient stratification in RA A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24% Next https://t.co/8ZZ2epf7LK

Links

https://x.com/AurelieRheumo/status/1964220962075005190/photo/1

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality &a

Tweet Author

RHEUMarampa

Tweet Content

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD. ☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb

Links

https://x.com/RHEUMarampa/status/1964217545202016537/photo/1

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow

Tweet Author

AurelieRheumo

Tweet Content

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H

Links

https://x.com/AurelieRheumo/status/1964218576426139723/photo/1

https://twitter.com/aurelierheumo/status/1963765001400758305

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵

Tweet Author

RHEUMarampa

Tweet Content

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Links

https://x.com/RHEUMarampa/status/1964197781163085839/photo/1

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment ?

Tweet Author

RHEUMarampa

Tweet Content

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment 📌Dont exclude any lumbar spine unless w/significant change like laminectomy 📌Can use in monitoring untreated pts since TBS declines @RheumNow #APLAR25 https://t.co/bcN83IDDja

Links

https://x.com/RHEUMarampa/status/1964182142780346407/photo/1

Topics

AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an

Antifibrotics - A New Class of Therapies in Rheumatology? Rheumatologists typically manage systemic autoimmune rheumat

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD

9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, id

Flow cytometry on Peripheral blood can help patient stratification in RA A cluster rich in TEMRA Terminally Differentia

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality &a

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment ?

Do you get our email newsletter?